Code is covered without prior authorization (high confidence)
Medicare Pricing
Work RVU
0.00
Facility
$3.01
Non-Facility
$3.01
Documentation Required
For any iontophoretic dermatologic or ophthalmologic application: documentation of agent(s) used, concentrations, device/model, current and duration parameters, and monitoring for local adverse effects (erythema, burns, corneal complications, etc.).
No documentation requirements are stated in this document chunk (bibliography).
For primary focal hyperhidrosis: documentation that the member is unresponsive to or unable to tolerate oral pharmacotherapy for excessive sweating (examples given: anti-cholinergics, beta-blockers, benzodiazepines).
For primary focal hyperhidrosis: documentation that significant disruption of professional and/or social life has occurred because of excessive sweating.
Key Coverage Criteria
(Inferred from references) Iontophoresis for treatment of rheumatoid arthritic knees
(Inferred from references) Transepithelial iontophoresis corneal collagen cross-linking for progressive keratoconus
(Inferred from references) Whole-finger iontophoresis to increase blood flow in systemic sclerosis
(Inferred from references) Transdermal iontophoretic drug delivery platforms/technologies (general)
(Inferred from references) Conservative treatments, including iontophoresis, for patellar tendinopathy
(Inferred from references) Alternatives to oral opioids for cancer/postoperative pain including fentanyl iontophoretic transdermal system (ITS)
Ask Verity about documentation requirements, denial risks, or coverage in your state.
For primary focal hyperhidrosis: documentation that topical aluminum chloride or other extra-strength antiperspirants are ineffective or cause a severe rash.
For delivery of local anesthetic before emergent skin puncture/dermatologic procedures: documentation of emergent nature of procedure and rationale for iontophoretic local anesthesia (i.e., need for more rapid dermal anesthesia than topical agents).